Bemcentinib selected as first candidate to be tested through new ACCORD study The Phase II clinical trial initiative to rapidly investigate bemcentinib’s efficacy and safety in hospitalised COVID-19 patients Study to be funded by the UK Department of Health and Social Care and UK Research and Innovation Study to be managed by CRO, IQVIA BerGenBio … Read more
Bemcentinib selected as first candidate to be tested through new ACCORD study The Phase II clinical trial initiative to rapidly investigate bemcentinib’s efficacy and safety in hospitalised COVID-19 patients Study to be funded by the UK Department of Health and Social Care and UK Research and Innovation Study to be managed by CRO, IQVIA BerGenBio … Read more
Bergen, Norway, 14 April 2020 – The board of directors in BerGenBio ASA (the “Company”) (OSE:BGBIO) has granted options to employees. The annual general meeting in the Company at 16 March 2020 approved the share options program and authorised the board of directors of the Company to issue share options to the Company’s employees as … Read more
Bergen, Norway, 30 March 2020 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 13 March 2020 where the Company announced the final results of the subsequent offering. A total of 6,397 shares were issued in the subsequent offering at a subscription price of NOK 18.00 … Read more
Bergen, Norway, 27 March 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, provides an update on its business and operations considering the ongoing COVID-19 outbreak. Summary BerGenBio’s priority remains the safety and health of its employees and their families, and to continue the Company’s … Read more
Bergen, Norway, 16 March 2020 – Annual general meeting of BerGenBio ASA was held at Clarion Hotel Bergen Airport, Flyplassveien 551, 5869 Bergen, on 16 March 2020. All proposals were resolved as presented in the notice convening the annual general meeting distributed on 24 February 2020, as further set out in the minutes from … Read more
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. … Read more
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. … Read more
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. … Read more
Bergen, Norway, 2 March 2020 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 20 February 2020 where the Company announced that an extraordinary general meeting had resolved to increase the Company’s share capital in connection with Tranche 2 of the private placement announced by the Company … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.